- Home
- HHS vs RVPH Comparison
HHS vs RVPH Comparison
Compare HHS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RVPH
- Stock Information
- Founded
- HHS 1923
- RVPH 2006
- Country
- HHS United States
- RVPH United States
- Employees
- HHS N/A
- RVPH N/A
- Industry
- HHS Advertising
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- RVPH Health Care
- Exchange
- HHS Nasdaq
- RVPH Nasdaq
- Market Cap
- HHS 30.3M
- RVPH 32.8M
- IPO Year
- HHS N/A
- RVPH N/A
- Fundamental
- Price
- HHS $3.38
- RVPH $0.39
- Analyst Decision
- HHS
- RVPH Strong Buy
- Analyst Count
- HHS 0
- RVPH 5
- Target Price
- HHS N/A
- RVPH $9.00
- AVG Volume (30 Days)
- HHS 29.6K
- RVPH 3.7M
- Earning Date
- HHS 08-07-2025
- RVPH 08-13-2025
- Dividend Yield
- HHS N/A
- RVPH N/A
- EPS Growth
- HHS N/A
- RVPH N/A
- EPS
- HHS N/A
- RVPH N/A
- Revenue
- HHS $181,355,000.00
- RVPH N/A
- Revenue This Year
- HHS $6.54
- RVPH N/A
- Revenue Next Year
- HHS N/A
- RVPH N/A
- P/E Ratio
- HHS N/A
- RVPH N/A
- Revenue Growth
- HHS N/A
- RVPH N/A
- 52 Week Low
- HHS $3.24
- RVPH $0.30
- 52 Week High
- HHS $8.52
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- HHS 32.45
- RVPH 35.22
- Support Level
- HHS $3.70
- RVPH $0.38
- Resistance Level
- HHS $4.03
- RVPH $0.45
- Average True Range (ATR)
- HHS 0.37
- RVPH 0.05
- MACD
- HHS -0.01
- RVPH 0.01
- Stochastic Oscillator
- HHS 0.00
- RVPH 17.57
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.